The Cloud Software Name Wall Street Just Repriced Higher

30‑Second Take

Why now? Four brokers repriced this name higher on August 7, and the stock still trades below every one of their targets.

Bank of America upgraded to Buy with a $175 target, up from $105. Oppenheimer went to $200 from $110 on Outperform. Macquarie moved to $170 from $130, and even neutral-rated UBS lifted its target to $160 from $95.

The trigger was fiscal Q4, reported August 6. Revenue came in at $1.77B against a $1.66B estimate, adjusted EPS hit $1.87 versus $1.50 expected, cloud revenue grew 31% and the company delivered its first GAAP-profitable quarter at a 12% operating margin.

The stock jumped about 35% on August 7 and closed Monday at $151.87. Yes, you missed the gap. You are still buying 17% below the 52-week high of $184 and 24% below the $188 average target, with the whole sell-side moving its numbers up rather than down.

The AI monetization story (Rovo, embedded AI across Jira and Confluence) is finally starting to convert into billings. That's the piece the market keeps underestimating.

Trade Setup

Time frame: Swing to medium-term (4 to 12 weeks)
Edge type: Post-earnings analyst rerating with the price still below consensus targets

Snapshot Table

Chart

1-Month Trading Summary: TEAM ground sideways in the $80 to $110 range for most of July, then gapped from $110.17 to $149.07 on August 7 after fiscal Q4 results, and added a little more Monday to close at $151.87.

That is a 37% two-session move, and it still leaves the price under the fresh $160 to $200 target band and under the $184 level the stock traded at last September.

A gap that size usually needs time to digest, so scale in rather than buying the whole position at once.

Bull Case 

Core thesis: Atlassian sells the collaboration and workflow software that keeps modern software teams running.

Jira for tickets. Confluence for docs. And now Rovo for AI agents sitting on top of both.

Its enterprise cloud migration story is still nowhere near done. Every customer still on data-center licenses is a future cloud upsell. That's runway you can count in years, not quarters.

Catalysts: Analyst conviction is stacking up. Four desks (BofA, Oppenheimer, Macquarie, UBS) lifted targets on the same morning, with the highest at $200. That's roughly 32% above where you can buy today, and the consensus target of $188 is 24% up.

When the sell-side clusters around a name like that, it usually means their models are getting more comfortable with the forward numbers.

Then there's the balance of the quarter itself. Subscription ARR reached $6.6B, up 23%, and remaining performance obligations grew 44% to $4.8B. That second number is contracted revenue you can see coming.

The AI product cycle is the fundamental engine. Rovo is Atlassian's AI agent layer inside Jira and Confluence, the piece that lets your teams automate ticket triage, doc summaries and workflow, and it's starting to show up in customer adoption. The market keeps underestimating how much this can lift average revenue per user across a base of hundreds of thousands of paying customers.

Valuation upside: Targets on TEAM now run from $160 to $200 with a $188 average, all above where the stock trades today. Forward P/E is about 28 on a business compounding cloud revenue in the low 30s.

Technical tailwind: The August 7 gap took price out of a months-long base on roughly 8.6 million shares, well above the 5.2 million daily average. Breakouts on that kind of volume tend to hold their gap.

Bear Case 

You need to know the downside before you buy.

Software multiples have been getting compressed all year as the market questions how much of the AI narrative is real revenue versus vibes. If macro sentiment sours, or the next print shows Rovo adoption softer than the analyst upgrade cycle implies, you'll see this one punished quickly.

Competition is the other thing worth watching. Microsoft's collaboration stack keeps pushing into Atlassian's turf, and Notion has been eating into the low end. Neither is existential yet. But if you see any slowdown in seat growth, it'll hit the multiple.

And here's the honest risk, the one the upgrade headlines skipped. Alongside the beat, Atlassian guided full-year revenue growth to roughly 13%, down from a prior outlook near 24%. Q1 guidance came in above consensus, but the annual number is a deceleration, and you are buying after a 37% two-day move.

If the next quarter shows any wobble in billings or cloud migration pace, the $200 targets get walked back as fast as they went up. Position accordingly, scale in, and keep a stop under the gap.

Quick Checklist 

✅ Thesis still valid after today's close
✅ Volume confirms move above key levels
✅ Next catalyst: fiscal Q1 2027 results, expected late October 2026

Deep‑Dive Links

• Latest earnings report

• Analyst ratings and price targets

• Short interest data

• Company profile and investor relations

That’s all for today’s Everyday Alpha. We’ll have a new pick for you every morning before the market opens, so stay tuned!

Best Regards,
—Noah Zelvis
Everyday Alpha